Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.

被引：0

作者：

Powderly, John ^{[1
]}

Shimizu, Toshio ^{[2
]}

LoRusso, Patricia ^{[3
]}

Razak, Albiruni ^{[4
]}

Miller, Kathy ^{[5
]}

Balar, Arjun ^{[6
]}

Bruix, Jordi ^{[7
]}

Michel, Loren ^{[8
]}

Blaney, Martha ^{[9
]}

Guan, Xiaowen ^{[9
]}

Lacy, Susan ^{[9
]}

Lally, Satwant ^{[9
]}

Lambert, Stacie ^{[9
]}

Leibman, Rachel ^{[9
]}

Vosganian, Gregory

Golan, Talia ^{[10
]}

Tolcher, Anthony ^{[11
]}

机构：

[1] Carolina Bio Oncol Inst, Huntersville, NC USA

[2] Natl Canc Ctr, Tokyo, Japan

[3] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[4] Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[6] NYU Langone Hlth, New York, NY USA

[7] Univ Barcelona, Barcelona, Spain

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] AbbVie Inc, Redwood City, CA USA

[10] Tel Aviv Univ, Oncol Inst Sheba Med Ctr Tel Hashomer, Tel Aviv, Israel

[11] New Expt Therapeut NEXT, San Antonio, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT207

引用

页数：2